<dfn id="oqcuf"></dfn>
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Animals were immunized with recombinant human follicle stimulating hormone receptor (FSHR) expressed in E. coli.
Spleen cells were fused with Sp2/0 mouse myeloma cells.The antibody recognizes the N-terminal extracellular domain (amino acids domain 23-358) of the human follicle stimulating hormone receptor (FSHR) (hormone binding unit).
The FSHR-18 (ATCC CRL-2688) and the FSHR-323 (ATCC CRL-2689) antibodies are additive. They recognize different epitopes.
The FSHR-323 antibody inhibits hormone binding and the hormone-induced activation of adenylate cyclase but the FSHR-18 antibody does not.
Vannier B, et al. Anti-human FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor. Biochemistry 35: 1358-1366, 1996. PubMed: 8634264
Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.
Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.
Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
